Literature DB >> 25083239

Drug-induced QT interval prolongation: mechanisms and clinical management.

Senthil Nachimuthu1, Manish D Assar1, Jeffrey M Schussler2.   

Abstract

The prolonged QT interval is both widely seen and associated with the potentially deadly rhythm, Torsades de Pointes (TdP). While it can occur spontaneously in the congenital form, there is a wide array of drugs that have been implicated in the prolongation of the QT interval. Some of these drugs have either been restricted or withdrawn from the market due to the increased incidence of fatal polymorphic ventricular tachycardia. The list of drugs that cause QT prolongation continues to grow, and an updated list of specific drugs that prolong the QT interval can be found at www.qtdrugs.org. This review focuses on the mechanism of drug-induced QT prolongation, risk factors for TdP, culprit drugs, prevention and monitoring of prolonged drug-induced QT prolongation and treatment strategies.

Entities:  

Keywords:  QT interval; Torsades de Pointes; drugs

Year:  2012        PMID: 25083239      PMCID: PMC4110870          DOI: 10.1177/2042098612454283

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  90 in total

1.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval.

Authors:  M Malik; P Färbom; V Batchvarov; K Hnatkova; A J Camm
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 2.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

3.  Exaggerated QT prolongation after cardioversion of atrial fibrillation.

Authors:  A M Choy; D Darbar; S Dell'Orto; D M Roden
Journal:  J Am Coll Cardiol       Date:  1999-08       Impact factor: 24.094

4.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

5.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

Authors:  M L De Bruin; M Pettersson; R H B Meyboom; A W Hoes; H G M Leufkens
Journal:  Eur Heart J       Date:  2005-01-06       Impact factor: 29.983

Review 6.  Congenital long QT syndromes: clinical features, molecular genetics and genetic testing.

Authors:  Chi-Keong Ching; Ene-choo Tan
Journal:  Expert Rev Mol Diagn       Date:  2006-05       Impact factor: 5.225

7.  Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.

Authors:  Arthur J Moss; Wojciech Zareba; Elizabeth S Kaufman; Eric Gartman; Derick R Peterson; Jesaia Benhorin; Jeffrey A Towbin; Mark T Keating; Silvia G Priori; Peter J Schwartz; G Michael Vincent; Jennifer L Robinson; Mark L Andrews; Changyong Feng; W Jackson Hall; Aharon Medina; Li Zhang; Zhiqing Wang
Journal:  Circulation       Date:  2002-02-19       Impact factor: 29.690

Review 8.  Understanding drug-induced torsades de pointes: a genetic stance.

Authors:  Prince J Kannankeril
Journal:  Expert Opin Drug Saf       Date:  2008-05       Impact factor: 4.250

Review 9.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

Review 10.  Sudden cardiac death in heart failure. The role of abnormal repolarization.

Authors:  G F Tomaselli; D J Beuckelmann; H G Calkins; R D Berger; P D Kessler; J H Lawrence; D Kass; A M Feldman; E Marban
Journal:  Circulation       Date:  1994-11       Impact factor: 29.690

View more
  70 in total

1.  Retrospective Diagnosis of Congenital Long QT Syndrome in a Patient With Febrile Syncope.

Authors:  Kory S London; Jessica Zegre-Hemsey; Melanie Root; Alex Kleinmann; Jennifer L White
Journal:  J Emerg Nurs       Date:  2020-03       Impact factor: 1.836

2.  Cannabidiol protects against high glucose-induced oxidative stress and cytotoxicity in cardiac voltage-gated sodium channels.

Authors:  Mohamed A Fouda; Mohammad-Reza Ghovanloo; Peter C Ruben
Journal:  Br J Pharmacol       Date:  2020-03-10       Impact factor: 8.739

Review 3.  Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis.

Authors:  Elena S Izmailova; William A Wood; Qi Liu; Vadim Zipunnikov; Daniel Bloomfield; Jason Homsy; Steven C Hoffmann; John A Wagner; Joseph P Menetski
Journal:  Digit Biomark       Date:  2021-04-22

4.  Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.

Authors:  Alexander Schmidt; Peter Fischer; Beate Wally; Joachim Scharfetter
Journal:  Neuropsychiatr       Date:  2017-08-08

5.  Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs.

Authors:  Anita N Bindraban; José Rolvink; Florine A Berger; Patricia M L A van den Bemt; Aaf F M Kuijper; Ruud T M van der Hoeven; Aukje K Mantel-Teeuwisse; Matthijs L Becker
Journal:  Int J Clin Pharm       Date:  2018-07-26

6.  George Ralph Mines (1886-1914): the dawn of cardiac nonlinear dynamics.

Authors:  Michael R Guevara; Alvin Shrier; John Orlowski; Leon Glass
Journal:  J Physiol       Date:  2016-05-01       Impact factor: 5.182

Review 7.  [Rational use of antibiotics].

Authors:  P Walger
Journal:  Internist (Berl)       Date:  2016-06       Impact factor: 0.743

8.  Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality: Prospective Cohort Study.

Authors:  Yoriko Heianza; Wenjie Ma; Xiang Li; Yin Cao; Andrew T Chan; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  Circ Res       Date:  2019-12-17       Impact factor: 17.367

Review 9.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.

Authors:  G C Bell; K E Caudle; M Whirl-Carrillo; R J Gordon; K Hikino; C A Prows; A Gaedigk; Jag Agundez; S Sadhasivam; T E Klein; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2017-04-06       Impact factor: 6.875

Review 10.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.